Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1981 Mar 7;282(6266):768-70.
doi: 10.1136/bmj.282.6266.768.

HLA-DR patterns in pernicious anaemia

HLA-DR patterns in pernicious anaemia

B Ungar et al. Br Med J (Clin Res Ed). .

Abstract

The pattern of HLA-DR antigens was studied in a group of 66 patients with Addisonian pernicious anaemia, comprising a subgroup of 18 patients with associated endocrine disease and a subgroup of 48 patients with no associated endocrine disease. Compared with a control group of 120 subjects all 66 patients showed an increase in HLA-DR2 and DR4 and a decrease in DR3 (p less than 0.02). Significant differences were also found between the endocrine and non-endocrine subgroups for patterns of HLA-DR antigens (p less than 0.005) and for pairwise combinations of HLA-DR antigens (p less than 0.01). Relative to controls, the endocrine subgroup showed an increase of HLA-DR3/DR4 (relative risk 4.0), contrasting with an increase of HLA-DR2/DR4 (relative risk 6.85) and DR4/DR5 (relative risk 5.38) in the non-endocrine subgroup. These observations suggest that HLA-DR antigens or closely linked genes may interact to influence susceptibility to pernicious anaemia (or endocrine disease, or both). Thus interactive effects related to HLA-DR2/DR4 and DR4/DR5 may predispose to pernicious anaemia without endocrine disease, whereas interactive effects related to HLA-DR3/DR4 may predispose to pernicious anaemia in association with endocrine disease.

PubMed Disclaimer

Similar articles

  • HLA patterns in pernicious anaemia.
    Ungar B, Mathews JD, Tait BD, Cowling DC. Ungar B, et al. Br Med J. 1977 Mar 26;1(6064):798-800. doi: 10.1136/bmj.1.6064.798. Br Med J. 1977. PMID: 856385 Free PMC article.
  • HLA and autoimmune endocrine disease 1985.
    Farid NR, Thompson C. Farid NR, et al. Mol Biol Med. 1986 Feb;3(1):85-97. Mol Biol Med. 1986. PMID: 3485759
  • Molecular identifications of HLA-DR4, MT3, and TB21 antigens on HLA-DR4 homozygous B cell lines.
    Maeda H, Hirata R. Maeda H, et al. J Immunol. 1984 Feb;132(2):574-7. J Immunol. 1984. PMID: 6418807
  • HLA-DR antigens in HBsAg-positive chronic active liver disease with and without associated delta infection.
    Forzani B, Actis GC, Verme G, Amoroso A, Borelli I, Curtoni ES, Rumi MG, Picciotto A, Marinucci G, Freni MA, et al. Forzani B, et al. Hepatology. 1984 Nov-Dec;4(6):1107-10. doi: 10.1002/hep.1840040602. Hepatology. 1984. PMID: 6594313
  • Endocrine Disease.
    De Sanctis V, Soliman AT, Skordis N, authors. Taher A, Porter J, editors. De Sanctis V, et al. In: Cappellini MD, Farmakis D, Porter J, Taher A, editors. 2021 Guidelines: For the Management of Transfusion Dependent Thalassaemia (TDT) [Internet]. 4th edition. Nicosia (Cyprus): Thalassaemia International Federation; 2023. CHAPTER 8. In: Cappellini MD, Farmakis D, Porter J, Taher A, editors. 2021 Guidelines: For the Management of Transfusion Dependent Thalassaemia (TDT) [Internet]. 4th edition. Nicosia (Cyprus): Thalassaemia International Federation; 2023. CHAPTER 8. PMID: 38683925 Free Books & Documents. Review. No abstract available.

Cited by

References

    1. Lancet. 1968 Aug 24;2(7565):415-7 - PubMed
    1. Lancet. 1969 May 10;1(7602):951-4 - PubMed
    1. Tissue Antigens. 1974;4(2):95-105 - PubMed
    1. J Immunol. 1977 Mar;118(3):943-6 - PubMed
    1. Br Med J. 1977 Mar 26;1(6064):798-800 - PubMed

Publication types

Substances

LinkOut - more resources